Navigation Links
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Date:7/16/2008

Network Data and Analysis Will Greatly Enhance Patient Safety and Reduce Healthcare Costs

BETHESDA, Md., July 16 /PRNewswire-USNewswire/ -- The U.S. Biovigilance Network, the nation's first and only nationwide data collection program for the transfusion and biological therapy communities, is preparing for a fall 2008 launch of its pilot. The Network has raised more than $1 million in private donations, including an $84,000 contribution by Fenwal Inc., one of the community's medical technology leaders. It has also secured support from hospitals and blood centers across the country.

The Network is a unique public/private collaboration with shared responsibilities for program development, operation and management, and funding. The federal government, through the Department of Health and Human Services, including the Centers for Disease Control and Prevention, has provided the platform for initial surveillance efforts through its National Healthcare Safety Network. The U.S. Biovigilance Network has raised $1 million in private contributions to fund the initial expenses and is seeking $2 million in additional support to complete development and implement the program.

"To ensure the safety of America's blood supply, it is vital that we create a centralized and standardized process for reporting adverse events," said Barbee Whitaker, Ph.D., AABB's Director of Data and Special Programs. "With data from the U.S. Biovigilance Network, we will be able to create a quality system that benefits patients, donors and the public health of the U.S."

The U.S. Biovigilance Network will, for the first time on a nationwide basis, collect and analyze data to identify trends and recommend best practices to reduce adverse reactions and incidents associated with blood transfusion and related biological therapies. Ultimately, the analyses of these data will enhance patient safety, make better use of blood and biological therapies, and reduce healthcare cos
'/>"/>

SOURCE AABB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Rep. Pickering to Receive First-Ever AVMA Advocacy Award
2. First International Cancer Film Festival Announces Finalists
3. Discovery first step to new therapies
4. Healthfirst and MD On-Line Partner to Streamline Claims Processing
5. Abaxis to Report First Quarter Fiscal 2009 Financial Results Thursday, July 24, 2008
6. Lutronic Announces FDA Clearance and Immediate Availability of Its eCO2, the First Multi-Functional Fractional CO2 Laser System
7. Stanford Bio-X researchers use needle-thin probe to get first look at working muscle fiber
8. Czech Republic to Host Historic First Global Conference on Methamphetamine
9. uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel
10. leViv Launches First Meal Programs Specifically Designed for Taste and Health
11. Drexel School of Public Health Uses NetReachs cmScribe Advanced Content Management System (CMS) Software for First National Diversity Preparedness Clearinghouse
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2